Paris - In the framework of the selection of its project by the Coalition Innovation Sante, Cureety announces it has obtained the institutional support of the Servier Group and Ipsen.
This support will enable an acceleration in the deployment of the Cureety telemonitoring solution for patients with cancer and who, in this health crisis context, have an increased need for medical monitoring. The Coalition Innovation Sante program, which brings together public and private healthcare players, contributes to easing the congestion in the healthcare system and ensures patients with chronic diseases continue to receive care despite the health crisis.
The Cureety platform is a CE-marked medical software device (class I) which makes it possible to monitor remotely and optimize the management of complex chronic diseases, first and foremost cancer. As a result of configurable algorithms and personalized questionnaires, the Cureety application is able to accompany the patient and direct him/her towards the most appropriate treatment.
In particular, the Cureety platform makes it possible to: Reassure patients by ensuring a daily link with their healthcare institution: patients can share their different symptoms via the application and receive tretament recommendations.
Streamline the medical time of carers who, thanks to the application, can prioritize the treatment of patients who need it most.
Facilitate and safeguard the arrival of patients in the day hospital for the administration of their treatment.
The Cureety telemonitoring solution is already being used in 20 hospital centers nationally and counts over 3000 patient users.
As a result of Servier and Ipsen's support, the deployment of the Cureety platform into healthcare institutions will be accelerated, which will ensure the continuity of oncology treatment is facilitated within the COVID-19 context. The Servier Group will finance the deployment of Cureety in 5 healthcare centers and Ipsen will finance the deployment of Cureety in 2 centers.
This ambitious program may be deployed in less than 3 weeks, in line with the objectives of the Coalition Innovation Sante and within the current urgent health context. The commitment of the laboratories Servier and Ipsen is key in making it possible for Cureety to reach this objective.
Contact:
Tel: +33 (0)6 70 07 87 47
About Cureety
Cureety is a startup created in March 2018 by Francois-Guirec Champoiseau and Hugo Breitwiller It is developing a CE-marked medical software device (class I) that makes it possible to monitor remotely and optimize the treatment of complex chronic diseases, first and foremost cancer. As a result of configurable algorithms and personalized questionnaires, the Cureety application is able to accompany patients and direct them to the most appropriate treatment. For healthcare teams, the platform allows them to streamline their resources and prioritize the treatment of the most vulnerable patients. Depending on the severity of the reported symptoms, the patient receives appropriate medical advice and, if needed, is encouraged to contact his or her healthcare team. Hospital services can therefore focus their efforts on the patients most in need and react more quickly, which should limit emergency hospitalizations. Cureety has a three-fold ambition. Cureety works to improve the quality of life of patients with complex diseases by accompanying them on a daily basis and by reacting in real time to their needs. Cureety innovates in the organization of hospital care by giving back time to medical teams without compromising the quality of patient care. Finally, Cureety also contributes to medical progress by collecting real-life data that will enable a better understanding of the management of patients with complex diseases. The solution is deployed in more than 20 healthcare institutions and ensures active monitoring of more than 3000 patients. Cureety is the winner of the 2019 class of AstraZeneca's REALIZE program, and incubated at Paris Biotech Sante at the Cochin Hospital in Paris. In 2020, Cureety is certified FrenchTechSeed.
About Ipsen
Ipsen is a global specialty-driven biopharmaceutical group focused on innovation and Specialty Care. The Group develops and commercializes innovative medicines in three key therapeutic areas - Oncology, Neuroscience and Rare Diseases. Its commitment to oncology is exemplified through its growing portfolio of key therapies for prostate cancer, neuroendocrine tumors, renal cell carcinoma and pancreatic cancer. Ipsen also has a well-established Consumer Healthcare business. With total sales over EUR2.5 billion in 2019, Ipsen sells more than 20 drugs in over 115 countries, with a direct commercial presence in more than 30 countries. Ipsen's R&D is focused on its innovative and differentiated technological platforms located in the heart of the leading biotechnological and life sciences hubs (Paris-Saclay, France; Oxford, UK; Cambridge, US). The Group has about 5,800 employees worldwide. Ipsen is listed in Paris (Euronext: IPN) and in the United States through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY).
IPSEN 
